PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
PepGen Inc. (PEPG)
Company Research
Source: GlobeNewswire
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy (DMD) patients whose mutations are amenable to an exon 51 skipping approach. PepGen is evaluating PGN-EDO51 for the treatment of DMD in the ongoing CONNECT1 Phase 2 trial, and expects to begin enrolling patients in the CONNECT2 Phase 2 trial later this year. “Receiving these FDA designations for PGN-EDO51 emphasizes the critical demand for novel and enhanced therapeutic options for people living with DMD,” said James McArthur, Ph.D., President and CEO of PepGen. “With our CONNECT1 Phase 2 trial underway, we look forw
Show less
Read more
Impact Snapshot
Event Time:
PEPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PEPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PEPG alerts
High impacting PepGen Inc. news events
Weekly update
A roundup of the hottest topics
PEPG
News
- PepGen to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- PepGen to Participate in Upcoming Investor ConferencesGlobeNewswire
- Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect? [Yahoo! Finance]Yahoo! Finance
- PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- PepGen Inc. (NASDAQ: PEPG) had its price target lowered by analysts at Wedbush from $21.00 to $20.00. They now have an "outperform" rating on the stock.MarketBeat
PEPG
Earnings
- 11/8/23 - Miss
PEPG
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/16/24 - Form PRE
- PEPG's page on the SEC website